You are here: Home » 2022 » Archives for June 2022

ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Okta, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – OKTA

NEW YORK, June 18, 2022 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Okta, Inc. (NASDAQ: OKTA) between March 5, 2021 and March 22, 2022, both dates inclusive (the "Class Period"), of the important July 19, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Okta securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Okta class action, go to https://rosenlegal.com/submit–form/?case_id=6365 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 19, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Okta had inadequate cybersecurity controls; (2) as a result, Okta's systems were vulnerable to data breaches; (3) Okta ultimately did experience a data breach caused by a hacking group, which potentially affected hundreds of Okta customers; (4) Okta initially did not disclose and subsequently downplayed the severity of the data breach; (5) all the foregoing, once revealed, was likely to have a material negative impact on Okta's business, financial condition, and reputation; and (6) as a result, the Company's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Okta class action, go to https://rosenlegal.com/submit–form/?case_id=6365 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8574456)

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Mullen Automotive, Inc. f/k/a Net Element, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm – MULN, NETE

NEW YORK, June 18, 2022 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mullen Automotive, Inc. f/k/a Net Element, Inc. (NASDAQ: MULN, NETE) between June 15, 2020 and April 6, 2022, inclusive (the "Class Period"), of the important July 5, 2022 lead plaintiff deadline in the securities class action commenced by the Firm.

SO WHAT: If you purchased Mullen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Mullen class action, go to https://rosenlegal.com/submit–form/?case_id=5459 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 5, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Mullen overstates its ability and timeline regarding production; (2) Mullen overstates its deals with business partners, including Qiantu Motors; (3) Mullen overstates its battery technology and capabilities; (4) Mullen overstates its ability to sell its branded products; (5) Net Element did not conduct proper due diligence into Mullen Technologies; (6) the Dragonfly K50 was not (solely) delayed due to the COVID–19 pandemic; and (7) as a result, defendants' public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Mullen class action, go to https://rosenlegal.com/submit–form/?case_id=5459 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8574472)

ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages LMP Automotive Holdings, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – LMPX

NEW YORK, June 18, 2022 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of LMP Automotive Holdings, Inc. (NASDAQ: LMPX) between June 29, 2021 and May 19, 2022, both dates inclusive (the "Class Period") of the important July 26, 2022 lead plaintiff deadline.

SO WHAT: If you purchased LMP securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the LMP class action, go to https://rosenlegal.com/submit–form/?case_id=6635 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 26, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) LMP engaged in the improper identification and elimination of intercompany transactions; (2) LMP used incorrect estimates for chargeback reserves for finance and insurance products; (3) LMP had misclassified certain items in its financial statements which impacting balance sheet and income statement financial statement captions; (4) there were material weaknesses in LMP's internal control over financial reporting; (5) as a result of the foregoing, LMP overstated its revenue; (6) as a result of the foregoing, LMP would restate certain of its previously issued financial statements and results; and (7) as a result of the foregoing, defendants' positive statements about LMP'S business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the LMP class action, go to https://rosenlegal.com/submit–form/?case_id=6635 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8574451)

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages IonQ, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – IONQ

NEW YORK, June 18, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of IonQ, Inc. (NYSE: IONQ) between March 30, 2021 and May 2, 2022, both dates inclusive (the "Class Period"), of the important August 1, 2022 lead plaintiff deadline.

SO WHAT: If you purchased IonQ securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the IonQ class action, go to https://rosenlegal.com/submit–form/?case_id=6703 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 1, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) IonQ had not yet developed a 32–qubit quantum computer; (2) IonQ's 11–qubit quantum computer suffered from significant error rates, rendering it useless; (3) IonQ's quantum computer is not sufficiently reliable, so it is not accessible despite being available through major cloud providers; (4) a significant portion of IonQ's revenue was derived from improper round–tripping transactions with related parties; and (5) as a result of the foregoing, defendants' positive statements about IonQ's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the IonQ class action, go to https://rosenlegal.com/submit–form/?case_id=6703 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8574465)

Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company’s President of Research & Development to Pursue Outside Opportunities

BOSTON and JERUSALEM, June 17, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that Dr. Phillip Schwartz, the Company's President of Research & Development and Founder, will resign from his current role effective July 21, 2022 to pursue other opportunities. Dr. Schwartz also stepped down from the Company's Board of Directors, effective June 15, 2022. Dr. Schwartz's resignation was not a result of any disagreement with the Company and Dr. Schwartz will remain as a consultant to the Company.

Bringing in his expertise from various development and commercialization roles at Merck KGaA–Serono and Endo Pharmaceuticals, Dr. Schwartz was a co–founder of Entera Bio in 2009 and led the Company as Chief Executive Officer through 2019 and its IPO in 2018. "We are grateful for Phillip's vision and leadership which have been paramount to the progression of Entera from an early stage R&D platform to a late stage clinical company with two core PTH programs in Phase 2/3 development and core R&D strategic partnerships, including with Amgen," said Mr. Jerry Lieberman, Chairman of the Board of Entera. "Under Dr. Schwartz's leadership, Entera Bio successfully navigated through over a decade of persistent growth and we remain indebted to his experience and contributions. In recent months, Entera has announced new leadership, which we believe will carry out Dr. Schwartz's vision for the Company at this critical stage in its evolution."

"Starting from a two person company in a small storage room of our apartment to a NASDAQ company with multiple clinical stage assets and a number of significant collaborations with biotech and other pharmaceutical companies has been the adventure of a lifetime. The Entera team is like family, and I will miss them greatly. I am very confident in the new management team, and am confident they will be able to move Entera forward to its next stage of development. I would like to express my gratitude to the Board of Directors and in particular to the employees and team at Entera who have made this progress possible and who have been creative, supportive and simply amazing to work with," stated Dr. Schwartz.

"After more than 12 years as Founder, CEO and President of R&D, I believe it is a good time for me to leave my position so that I can spend more time with my family and pursue other opportunities. I remain very excited by the Company's prospects and the potential of our compounds to change the treatment paradigm of patients with osteoporosis, hypoparathyroidism and other serious illnesses. Our lead compound, EB613, is moving into Phase 3 pivotal clinical development and has the potential to serve as the first oral anabolic for the treatment of osteoporosis. Currently, approximately 30% of the 15 million women with osteoporosis are on any form of treatment, and of those, only a fraction are on any form of bone building/anabolic agent. Being an oral medication is one of the primary drivers for acceptance of a treatment in osteoporosis. As such, an oral bone building agent like EB613 holds the potential to be transformative to a much expanded base of osteoporotic patients. Likewise, EB612 is a highly differentiated treatment candidate for hypoparathyroidism which promises to greatly improve the treatment of this serious illness. With the development of these drugs, as well as an excellent validated platform technology for the development of other oral formulations of world class biological drugs, I am confident that the recent strengthening of Entera's management team will be successful in achieving our strategic goals and increasing shareholder value. I look forward to continuing to advise Entera going forward."

About Entera Bio
Entera is a leader in the development of orally delivered peptides and therapeutic proteins for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company's proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company's most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com.

Forward Looking Statements

Various statements in this release are "forward–looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward–looking statements. Words such as, but not limited to, "anticipate," "believe," "can," "could," "expect," "estimate," "design," "goal," "intend," "may," "might," "objective," "plan," "predict," "project," "target," "likely," "should," "will," and "would," or the negative of these terms and similar expressions or words, identify forward–looking statements. Forward–looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.

Important factors that could cause actual results to differ materially from those reflected in Entera's forward–looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA's interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera is contractually obligated to provide, such as those pursuant to Entera's agreement with Amgen; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera's product candidates; Entera's reliance on third parties to conduct its clinical trials; Entera's expectations regarding licensing, business transactions and strategic collaborations; Entera's operation as a development stage company with limited operating history; Entera's ability to continue as a going concern absent access to sources of liquidity; Entera's ability to obtain and maintain regulatory approval for any of its product candidates; Entera's ability to comply with Nasdaq's minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera's intellectual property position and its ability to protect its intellectual property; and other factors that are described in the "Cautionary Statements Regarding Forward–Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Entera's most recent Annual Report on Form 10–K filed with the SEC, as well as the company's subsequently filed Quarterly Reports on Form 10–Q and Current Reports on Form 8–K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward–looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward–looking statements Entera makes in this press release. The information in this release is provided only as of the date of this release, and Entera undertakes no obligation to update or revise publicly any forward–looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.


GLOBENEWSWIRE (Distribution ID 8574219)

Infant Formula Producers Facing Crisis Can Rely on Southern California ProTab Labs for Safe Rapid Large-Scale Production of Premixes and Packaging Solutions

Foothill Ranch, Calif., June 16, 2022 (GLOBE NEWSWIRE) — To tackle the infant formula crisis, producers can rely on Southern California supplement solutions contract manufacturer ProTab Laboratories to blend custom premixes and produce and package infant formula with a rapid turnaround time.

"ProTab is in the perfect position as a supplement solution manufacturer and packager to prioritize infant formula production with safety and scale to help replenish the supply in the market," said Joanne Hsu, vice president of operations. "We are ready to produce safe, high–quality premixes with careful processing and top–quality standards at our facility for reassuring parents and babies that they will have access to quality and safe infant formula."

Safety continues to be at the forefront of the crisis. ProTab has the capabilities of in–house analytical laboratory services for quality control validation, including analytical capabilities. The company is FDA registered with cGMP, FSMA, and FSSC 22000 certified by NSF.

"ProTab can rapidly turn around the production of powder and premix for liquid infant formula at a large scale to bolster the supply of products with proper FDA–inspected nutritional values and safety," said Hsu. "Our certifications are the gold standard of safety for reassuring our manufacture of food and supplement solutions, including infant formula premix solutions."

"As a GFSI certified producer and packager of supplement solutions, ProTab elevates food safety to the next level with our state–of–the–art facility, coupled with our quality control procedures and testing," said Fariba Samadi, director of quality assurance and regulatory affairs. "Following stringent quality assurance and safety processes, we evaluate the quality of raw materials before manufacturing as well as the finished goods."

Infant formula producers can leverage ProTab's modern technology for precision blending needed for producing infant formula. Microencapsulation is offered to mask the undesirable characteristics of particular additives and formula ingredients. The technology is part of ProTab's recent multimillion–dollar expansion to increase the footprint for blending and mixing premix solutions.

ProTab can also help secure the best materials and ingredients if needed; the company keeps up with the newest production and delivery technologies and the latest regulatory requirements and considers modern formulation and consumer trends.

For specific needs in labeling and standards, ProTab Labs can manufacture products to the specification of USDA Organic, Non–GMO Project Verified, Halal, and Kosher. The company is registered with Health Canada as a foreign manufacturer site.

"We encourage infant formula manufacturers and brand holders to bring their formulas and packaging schematics to work with us," said Hsu. "We are confident in helping everyone get through the bottleneck together and positioning ProTab as a long–term infant formula production partner," said Hsu.

###

About ProTab Laboratories
ProTab Laboratories is a custom research contract manufacturer operating a state–of–the–art facility in Southern California for providing rapid turnaround services for tablet, capsule, and powder form products, along with high–capacity mixing processes for nutritional and dietary supplements, tableting, microencapsulation, granulation, and milling. ProTab can guide brands through the product development and technical process from inception to the final product.

Contact us at info@protablabs.com.

For brands that would like to strengthen their vendor diversity profile, ProTab is also a certified Women–Owned Business Enterprise.

Certifications
ProTab's manufacturing operation is fully compliant with all current Good Manufacturing Practices (cGMP) established within the industry and meets or exceeds all quality standards for Nutritional Supplements. The company has established Standard Operating Procedures (SOP) to ensure that this standard is met in all manufacturing process phases. Our quality control standards are compliant with Kosher, Halal, Health Canada, USDA Organic, State of California Department of Public Health, NSF, and Non–GMO Project Verified.

Attachments


GLOBENEWSWIRE (Distribution ID 8573413)

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages HUMBL, LLC Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – HMBL

NEW YORK, June 15, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of HUMBL, LLC (OTC: HMBL) and/or the Company's unregistered digital asset (sold as BLOCKS Exchange Traded Index ("ETXs") on various cryptocurrency exchanges) between November 1, 2020 and May 19, 2022, both dates inclusive (the "Class Period") of the important July 19, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Humbl securities and/or the Company's ETXs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Humbl class action, go to https://rosenlegal.com/submit–form/?case_id=6398 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 19, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants violated provisions of the Exchange Act by making false and misleading statements concerning the Company's growth prospects, technological advancements, international partnerships, and financial benefits for Humbl common stock and digital asset investors, as well as using selectively timed announcements to keep Humbl stock price high so that Company insiders could sell off their holdings into artificially created volume. The complaint also alleges that defendants violated provisions of the Securities Act by selling its unregistered securities (BLOCK ETX digital assets) to investors.

To join the Humbl class action, go to https://rosenlegal.com/submit–form/?case_id=6398 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8573182)

ROSEN, A TOP RANKED LAW FIRM, Encourages First High-School Education Group Co., Ltd. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FHS

NEW YORK, June 15, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of First High–School Education Group Co., Ltd. (NYSE: FHS) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's March 2021 initial public offering ("IPO" or the "Offering") of the important July 11, 2022 lead plaintiff deadline.

SO WHAT: If you purchased First High–School Education Group securities pursuant and/or traceable to the Registration Statement you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the First High–School Education Group class action, go to https://rosenlegal.com/submit–form/?case_id=6131 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 11, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the IPO Registration Statement was materially false and misleading and omitted to state: (1) the new rules, regulations, and policies to be implemented by the Chinese government following the Two Sessions parliamentary meetings were far more severe than represented to investors and posed a material adverse threat to First High–School Education Group and its business; (2) contemplated Chinese regulations and rules regarding private education were leading to a slowdown of government approval to open new educational facilities which would have a negative effect on First High–School Education Group's enrollment and growth; and (3) as a result, the Registration Statement's representations regarding First High–School Education Group's historical financial and operational metrics and purported market opportunities did not accurately reflect the actual business, operations, and financial results and trajectory of First High–School Education Group at the time of the IPO, and were materially false and misleading and lacked a factual basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the First High–School Education Group class action, go to https://rosenlegal.com/submit–form/?case_id=6131 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8573172)

ROSEN, A LEADING LAW FIRM, Encourages Digital Turbine, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – APPS

NEW YORK, June 15, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Digital Turbine, Inc. (NASDAQ: APPS) between August 9, 2021 and May 17, 2022, both dates inclusive (the "Class Period"), of the important August 5, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Digital Turbine securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Digital Turbine class action, go to https://rosenlegal.com/submit–form/?case_id=6272 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 5, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: The complaint filed in this class action alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about Digital Turbine's business, operations, and prospects. Specifically, defendants failed to disclose to investors that: (1) Digital Turbine's recent acquisitions, AdColony and Fyber, act as agents in certain of their respective product lines; (2) as a result, revenues for those product lines must be reported net of license fees and revenue share, rather than on a gross basis; (3) Digital Turbine's internal control over financial reporting as to revenue recognition was deficient; (4) as a result of the foregoing, Digital Turbine's net revenues was overstated throughout fiscal 2022; and (5) as a result of the foregoing, defendants' positive statements about Digital Turbine's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Digital Turbine class action, go to https://rosenlegal.com/submit–form/?case_id=6272 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8573163)

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Dentsply Sirona Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – XRAY

NEW YORK, June 15, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the common stock of Dentsply Sirona Inc. (NASDAQ: XRAY) between June 9, 2021 and May 9, 2022, both dates inclusive (the "Class Period"), of the important August 1, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Dentsply common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Dentsply class action, go to https://rosenlegal.com/submit–form/?case_id=6111 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 1, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) defendants orchestrated a scheme to inflate Dentsply's revenue and earnings by manipulating its accounting for a distributor rebate program in order for senior executives to be eligible for significant cash and stock–based incentive compensation; (2) in order to facilitate this scheme, Dentsply and its executives made numerous false and misleading statements to investors during the Class Period; (3) accordingly, Dentsply's financial statements were not prepared in accordance with GAAP and SEC rules, and Dentsply's internal controls over financial reporting were deficient throughout the Class Period; and (4) as a result of defendants' misrepresentations, Dentsply's common stock traded at artificially inflated prices during the Class Period. As a result of the foregoing, When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Dentsply class action, go to https://rosenlegal.com/submit–form/?case_id=6111 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8572950)